Triangulating evidence in health sciences with Annotated Semantic Queries

- **3** Yi Liu^{1,*} and Tom R Gaunt^{1,2,*}
- ⁴ ¹MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK
- ⁵ ²NIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, UK
- ⁶ ^{*}corresponding authors

7 ABSTRACT

Integrating information from data sources representing different study designs has the potential to strengthen evidence in population health research. However, this concept of evidence "triangulation" presents a number of challenges for systematically identifying and integrating relevant information. We present ASQ (Annotated Semantic Queries), a natural language query interface to the integrated biomedical entities and epidemiological evidence in EpiGraphDB, which enables users to extract

⁸ "claims" from a piece of unstructured text, and then investigate the evidence that could either support, contradict the claims, or offer additional information to the query. This approach has the potential to support the rapid review of pre-prints, grant applications, conference abstracts and articles submitted for peer review. ASQ implements strategies to harmonize biomedical entities in different taxonomies and evidence from different sources, to facilitate evidence triangulation and interpretation. ASQ is openly available at https://asq.epigraphdb.org.

⁹ Compiled at 2022-04-12 16:38.

10 **1 Introduction**

Researchers in health sciences are encouraged to seek multiple strands of complementary ev-11 idence to minimise the risk of bias creating false positives. This has been referred to as the 12 triangulation¹ of evidence, which may combine results from different study designs with differ-13 ent sources of bias, including from established findings in the literature. Platforms which offer 14 a portal to integrated heterogeneous data such as Open Targets² and EpiGraphDB³ are highly 15 valuable sources which have the potential to support evidence triangulation by integrating evi-16 dence with relevant information from a range of dedicated data providers, including biomedical 17 ontologies⁴⁵, genetic associations⁶ and literature-derived evidence⁷. One of the main objec-18 tives for the web interface of such integrated data platforms is to present users with focused in-19 formation from various integrated sources in order to facilitate the fast navigation and discovery 20 of evidence. However, there is a need to improve accessibility of such complex data resources 21 for less experienced users and to improve the interpretability of data, transforming source data 22 into comprehensible evidence and knowledge regarding a research question. There are several 23 challenges in order for these issues to be addressed, such as: how can a research question be 24 represented so that evidence can be retrieved for triangulation, how should we integrate biomed-25 ical entities from different taxonomies and their relationships, and what strategies should we use 26 to form larger evidence groups from heterogeneous source data and methods to prioritise the 27 retrieved evidence? 28

We approach the above-mentioned challenges by developing a scientific claim guery plat-29 form Annotated Semantic Queries (ASQ; https://asq.epigraphdb.org) on top of the in-30 tegrated biomedical knowledge and evidence of the EpiGraphDB³ data and ecosystem, where 31 users are able to investigate the various groups of evidence that support / contradict a claim, 32 and assist their further investigation into the source data that relates to that claim. Scientific 33 claims from a query text (e.g. the abstract of a pre-print) are parsed into claim triples (in the 34 form of Subject PREDICATE Object) in ASQ, where the subject and object terms are an-35 notated with ontology terms and then mapped to evidence entities in an *entity harmonization* 36 process, by a combination of high-dimensional text embeddings and sequence classification 37 methods. Evidence from difference sources are then retrieved and harmonized into two groups 38 a triple and literature evidence group comprised of literature and literature-derived evidence. 39 and an association evidence group comprised of statistical association results from systematic 40 analyses. Evidence items are then assigned with scores that reflect their strength as well as 41 their relevance to the claim, so that ASQ is able to present evidence which would be of poten-42 tial high value to the user in order for them to assess and triangulate the evidence regarding a 43 scientific claim. Here we discuss the implementation of the ASQ platform and components and 44 demonstrate its use for systematic analysis of claims derived from MedRxiv⁸ submissions from 45 2020 to 2021. 46

47 2 Results

48 2.1 The EpiGraphDB-ASQ platform

49

[Figure 1 here]

The ASQ platform is developed as a natural language interface component to the epidemi-50 ological evidence integrated in EpiGraphDB database and ecosystem (Figure 1), with the aim 51 of allowing users to access EpiGraphDB knowledge and triangulate the evidence using a sim-52 ple scientific claim of interest as a starting point. For example, instead of relying on bespoke 53 topic-specific web gueries that are restricted to several entities or meta-entities or via struc-54 tural gueries to the database, ASQ presents the integrated evidence from EpiGraphDB as in-55 trospectable evidence items that "fact-check" a claim "glucose can be used to treat diabetes" 56 (Figure 2) or a short piece of text containing multiple such claims. 57

58

[Figure 2 here]

⁵⁹ Various components of epidemiological evidence from EpiGraphDB are incorporated into ⁶⁰ the ASQ platform as two **evidence groups** (Table 1):

 A triple and literature evidence group which consists of both the semantic triples derived 61 from literature sources that are integrated from SemMedDB⁷ and the source literature 62 articles from PubMed from which the triples are derived (Supplementary tables 1 and 63 2). Typically an evidence item in this group is comprised of a semantic triple in the form 64 of Subject-PREDICATE-Object (e.g. "Obesity CAUSES Asthma") and the multiple 65 source literature items containing specific context details in the literature title and abstract 66 text. SemMedDB imports parsed entities and triples from SemRep⁹ which normalizes 67 terms mentioned in a text document into UMLS Metathesaurus entities¹⁰ and predicate 68 relationships into Semantic Network relationships¹¹. 69

2. An association evidence group which consists of various sources of curated systematic 70 statistical association analysis studies using systematic Mendelian Randomization analy-71 ses (the [MR_EVE_MR]¹² relationships in EpiGraphDB data; see Supplementary Table 4 72 for notation conventions), genetic correlations (the [GEN COR]¹³ relationships), and poly-73 genic risk score associations (the [PRS]¹⁴ relationships), where the analyses are con-74 ducted between two human traits for which genome-wide association study (GWAS) data 75 are curated by OpenGWAS⁶ (the (Gwas) nodes in EpiGraphDB). ASQ incorporates the 76 common properties of effect size, standard error, P-Value, as well as source/target GWAS 77 traits from the source analysis data as the common quantitative/qualitative information of 78 the evidence items, and additional detailed source-specific properties are also retrieved 79 for users' own investigation. 80

[Table 1 here]

81

On the web interface, the main entry point for a user to interact with the platform is to input 82 short paragraphs of scientific text (e.g. the abstract of a journal article or pre-print). From this in-83 put we use SemRep⁹ as the query parser to derive **query claim triples** from the text in the form 84 of Subject-PREDICATE-Object (e.g. "Obesity CAUSES Asthma"). The user is then asked 85 to select a specific triple of interest as the target of the downstream stages of entity harmoniza-86 tion and evidence retrieval. Alternatively, users can either directly input a query claim in the 87 query triple view (https://asq.epigraphdb.org/triple), or start from the MedRxiv sys-88 tematic analysis summary results (https://asq.epigraphdb.org/medrxiv-analysis). 89 In the following entity harmonization stage, ASQ harmonizes the biomedical entities from 90 the claim triple with the Experimental Factor Ontology (EFO⁵) entities, with the EFO ontology 91 serving as the anchor to connect the query entities and any evidence entities (Section 4.1). By 92 default ASQ attempts to retrieve entities that are semantically highly related (but not exclusively 93 identical) to the query entities to allow for exploratory discovery about further evidence of po-94 tential interest. This can be adjusted to more restrictive (specific) or more liberal (sensitive) 95 mapping. 96

In the *evidence retrieval* stage, evidence items from the two evidence groups are retrieved 97 based on the biomedical entities harmonized in the previous stage, as well as on the predi-98 cate direction group ("directional" and "non-directional") of the claim triple. Evidence items 99 are then categorised into several evidence types (Section 4.2): (a) supports the query claim 100 ("supporting"), (b) contradicts with the query claim with retrieved items indicating evidence in 101 the opposite direction to the claim ("reversal"), (c) fail to meet the required evidence threshold 102 to be supporting or contradictory ("insufficient") or (d) could be of additional information ("addi-103 tional") to the claim. Retrieved individual evidence item and groups of items are then measured 104 with a score to reflect both the proximity of the involved entity to the query claim as well as 105 the strength of the evidence (Section 4.3). For triple and literature evidence the strength of the 106 evidence item is calculated based on the number of literature sources, whereas for associa-107 tion evidence the strength is calculated based on the standardized effect size. The evidence 108 strength score is then adjusted by a mapping score measuring the semantic similarities between 109 the subject/object terms of the evidence item and those of the query claim. 110

ASQ provides comprehensive information (Figure 3) regarding the status of entity harmonization with summary diagrams describing the mapped ontology entities and harmonization metrics linking the evidence entities to the original query claim. For triple and literature evi-

dence, users can further introspect the context detail from which the semantic triples are derived, and for association evidence, ASQ displays the statistical results on forest plots as quantitative comparisons. In addition to the default interactive session on the web interface, ASQ offers programmatic access via the API (See "Code availability" section) which allows for batch processing and analysis (e.g. Section 2.2).

[Figure 3 here]

119

2.2 Systematic analysis of MedRxiv submissions

121 2.2.1 Study design

We demonstrate the use of ASQ by systematically analysing the preprint submissions on MedRxiv 122 in the sample period from 2020-01-01 to 2021-12-31 (Figure 4). We will further discuss the tech-123 nical details and the relevant terminology covered here in Section 4. Using the MedRxiv/BioRxiv 124 API, we identified 28,846 unique submissions in the period (in the case of multiple versions in 125 a submission we kept only the initial version) and retrieved their abstracts as candidate text 126 documents containing multiple scientific claims to be parsed in SemRep. Out of all the candi-127 date documents, 13,999 documents were successfully parsed by SemRep to contain coherent 128 semantic triples at sentence level, and 6,870 documents were identified to contain suitable pred-129 icates for analysis in ASQ. In total we extracted 13,295 document-triples (14,436 claim triples) 130 as the sample dataset. 131

Each claim triple was processed through ASQ programmatically to map with EFO and ev-132 idence entities in the entity harmonization stage using a set of parameters which are equiv-133 alent to the default settings used in the web interface (see Supplementary Table 5 for con-134 figuration of parameters), with 1,446 document-triples identified to be valid and associated 135 with entities in EpiGraphDB. Amongst these document-triples, we found that "Disease or Syn-136 drome" is the most numerous semantic group (888 query terms, 7,831 EFO entities), followed 137 by "Mental or Behavioral Dysfunction" (125 query terms, 1,708 EFO entities), and "Neoplas-138 tic Process" (138 query terms, 1,516 EFO entities) (Supplementary Table 7). In order to 139 avoid the document-triple dataset for analysis being too large we used the intersection sub-140 set where a document-triple must contain at least one type of evidence in both the triple 141 and literature evidence group and the association evidence group (Supplementary Table 6 142 reports the summary statistics). The final dataset consisted of 412 claim triples (337 sub-143 mission abstracts, and 386 document-triples) where each claim is associated with retrieved 144 evidence from multiple evidence types across the evidence groups, and can be accessed via 145 https://asg.epigraphdb.org/medrxiv-analysis with the option to adjust settings for 146 individual query cases. 147

148

[Figure 4 here]

¹⁴⁹ 2.2.2 Systematic results from entity harmonization and evidence retrieval

In the entity harmonization stage of the systematic analysis, the retrieval of EFO entities is determined by an initial stage where EFO candidates are retrieved by the semantic similarities between the EFO candidates and the query subject/object terms by their encoded text vectors, and a subset is subsequently selected based on proximity of the query term and the candidates in the EFO graph as indicated by the identity scores, which then gets mapped to evidence entities via semantic similarities (See Section 4.1). Figure 5 shows the distribution of score

metrics for the entity harmonization process where guery terms are mapped to EFO entities 156 and Supplementary Figure 1 shows the distribution of scores for mappings of evidence entities 157 to the original query terms. For selected entities which have identity scores below the threshold 158 in the automated process, they would also be semantically closer to the query terms than the 159 rest of the retrieved candidates (with mean semantic similarity scores above 0.9), and therefore 160 from a systematic scale ASQ is able to select a set of corresponding EFO entities that have high 161 association to the query terms of interest as the basis for further retrieving evidence entities 162 related to these guery terms. Similar automated approach applies in the interactive session, 163 and users are able to optionally override the automated processing of entity harmonization with 164 manual selection of EFO entities of interest or re-adjust the entity selection afterwards. 165

166

[Figure 5 here]

Figure 6 shows the distribution of the evidence scores and their constituent scores in the 167 evidence retrieval process, and further details are available in the supplementary materials on 168 group specific distributions (Supplementary Figures 4 and 5), as well as on summary statistics 169 (Supplementary Table 8). The mean mapping score for retrieved evidence is around 0.5 to 0.7, 170 with a typical scenario where the retrieved entities have about 0.85 to 0.92 in semantic similarity 171 to its upstream entities. The mean strength score for *triple and literature evidence* is around 1, 172 i.e. on average a triple evidence item was identified in only 1 source literature item, though 173 there is a long upper tail with many cases of 10 to 20 source literature items associated with a 174 triple (i.e. strength scores around 2 to 2.3). Association evidence items are required to have 175 sufficient strength of effect size in order to qualify into the "supporting" type or the "reversal" 176 type (otherwise they would be of "insufficient" evidence), and therefore the strength scores for 177 "supporting" and "reversal" types are markedly higher than items in the "insufficient" type. In 178 general, the evidence scores for "supporting" and "reversal" association evidence are found to 179 be distributed around the baseline score of 1. In addition, as constituent scores the mapping 180 scores and strength scores contribute to the evidence scores in roughly linear relationships 181 (Supplementary Figures 2 and 3). 182

183

[Figure 6 here]

184 2.2.3 Top cases of research areas

Whilst results from the systematic analysis reflect the availability of evidence in ASQ and 185 EpiGraphDB in various areas, they also show the popular research topics and themes reflected 186 from MedRxiv submissions in 2020-2021. Figure 7 shows several clusters of research areas 187 with central terms as measured in Table 2, and example claim triples can be found in Sup-188 plementary Table 9. In addition to research associated with the COVID-19 pandemic ("Coro-189 navirus infections"), the two areas with highest research submissions and retrieved evidence 190 are regarding obesity and associated diseases ("Obesity", "Diabetes", "Diabetes Mellitus, Non-191 Insulin-Dependent", "Chronic Kidney Diseases", etc.) and mental health ("Depressive disorder" 192 "Parkinson Disease", "Alzheimer's Disease", "Schizophrenia", etc.). Notably when SemRep fails 193 to recognize a more specific term it will fall back to more general terms, and therefore the term 194 "Disease" is prominent in the list of top terms. Examples in Supplementary Table 9 suggest 195 claims involving predicates "CAUSES", "AFFECTS" and "COEXISTS WITH" are the most pop-196 ular claims that can be derived from submitted abstracts, which is similar to the summarised 197 results in all cases in Supplementary Table 8 where these predicates are the ones with most 198 retrieved evidence items. 199

[Table 2 here]

[Figure 7 here]

200

202 2.2.4 Individual case

Here we showcase an example in demonstrating the use of ASQ for researchers in triangulat-203 ing evidence regarding epidemiological research questions. From the systematic dataset, ASQ 204 extracted a claim triple "Obesity CAUSES Heart failure" from a preprint abstract regarding a 205 Mendelian randomization analysis investigating causal relationships between body mass index 206 and heart failure risk¹⁵, derived from the context "About 40% of the excess risk of HF due to 207 adiposity is driven by SBP, AF, DM and CHD", where "HF" is recognised as heart failure and "adi-208 posity" as obesity. These results can be found on ASQ (https://asg.epigraphdb.org/ 209 triple?subject=Obesity&object=Heart%20failure&predicate=CAUSES&analysis 210). The guery subject "Obesity" and object "Heart failure" were mapped to their corresponding on-211 tology counterparts then to evidence entities, from which ASQ then identified suitable evidence 212 items. At aggregate level for triple and literature evidence there are more supporting evidence 213 items (11) with higher aggregated scores (12.80) compared to reversal evidence items (6) with 214 lower aggregated scores (5.46), similarly there are 5 supporting association evidence items 215 with an aggregated score of 5.11 with no reversal evidence identified. Users are able to further 216 investigate the literature that either associate with the claim triple (e.g.¹⁶ and¹⁷) or the rever-217 sal claim that heart failure might cause obesity (e.g.¹⁸), viewing the surrounding context from 218 the abstract directly in the ASQ interface, or clicking a link to access the original paper. For 219 association evidence ASQ identified several individual findings from the pairwise Mendelian 220 randomization studies with sufficient statistical significance as supporting evidence. ASQ also 221 identified a range of findings that are insufficient in statistical significance to qualify as support-222 ing evidence, which are useful both in showing the scope of evidence identification but also in 223 determining the cause of a lack of reversal evidence. In this case, the lack of reversal evidence 224 was due to absence of results from the MR-EvE data source (as there were no retrieved in-225 sufficient counterparts to reversal evidence items). In addition, ASQ identified several findings 226 from the PRS Atlas data source, and since the identified trait term "Target heart rate achieved" 227 was not directly equivalent to the query object "Heart failure" ASQ would assign low evidence 228 scores to these findings in the context of the original claim. In general ASQ is able to assist 229 researchers in investigating research questions in epidemiology both at aggregate level to have 230 an overview of the evidence categories regarding the question, as well as at individual level for 231 researchers to further investigate the evidence items in literature or statistical findings with their 232 expert knowledge. 233

234 3 Discussions

We developed the Annotated Semantic Queries (ASQ) platform as an approach to improve the 235 accessibility of the EpiGraphDB data and ecosystem for users through the implementation of a 236 natural language interface (whilst also enhancing programmatic access). There is an intrinsic 237 problem with integrated data platforms containing rich and complex data: experienced users 238 wish to be presented with flexible access to the data in order to navigate to the elements they 239 want, yet new users can find this complexity overwhelming (even if well documented). From 240 this perspective ASQ provides an accessible natural language query interface for such users to 241 find the evidence relating to a specific claim/question e.g. "Can obesity cause asthma?", which 242

can either be parsed from a short piece of text containing scientific claims, or directly input as 243 a claim triple of Subject PREDICATE Object. In addition to providing a more accessible 244 interface to EpiGraphDB this approach provides a novel way to systematically evaluate a piece 245 of text (such as a pre-print abstract) to identify whether claims within that text are supported 246 by other data. Heterogeneous knowledge types are harmonized in ASQ into intuitive evidence 247 aroups making triangulation of evidence in different groups more accessible, without either the 248 need to navigate to various area-specific topics or the need to formulate complex queries. As 249 we have demonstrated with our systematic analysis, the evidence retrieved by ASQ can be 250 of high value and relevance to a wide range of researchers epidemiology and health science 251 to assist the triangulation of evidence in their research. This is a generalisable approach that 252 could be applied to a wider array of knowledge graphs and evidence sources to support the 253 development of tools for rapid "semi-automated" (assisted) review of pre-prints. 254

Recent advances in deep learning modelling have contributed to a significant improvement 255 in natural language processing, and ASQ applies our previous method development¹⁹ in com-256 bining sequence classification Transformer models with text vector embeddings for the harmo-257 nization of entities in different taxonomies. ASQ is able to combine the functionalities of parsing 258 free text to generate structural claims with the harmonization of heterogeneous entities and 259 evidence to enable claims to be mapped to with evidence both from literature and semantic 260 knowledge as well as evidence from systematic association analysis. As part of the ASQ plat-261 form we developed a scoring mechanism to prioritise the retrieved evidence item, accounting 262 for the semantic relevance of entities to the query of interest, as well as the strength of the 263 evidence item per se. This score enables users to rapidly evaluate a wide range of evidence. 264 whilst at the same time being able to assess the value of individual evidence items or evidence 265 groups to the query to enable prioritisation. 266

On the other hand, it is worth pointing out that users should not be relying on metrics 267 (whether they are ranking metrics, P-Values, or discrete categories of "accepting" / "incon-268 clusive" / "rejecting") as sole criteria when assessing evidence or as a substitute for detailed 269 investigation, not just in ASQ but also interacting with data platforms. The nature of the hetero-270 geneous source data means we strongly recommend users spend time investigating individual 271 evidence sources using links provided by ASQ, as well understanding the various harmoniza-272 tion strategies in ASQ's documentation, since data harmonization in itself is an opinionated way 273 of data retrieval which might not be aligned with individual use cases. We seek to continue 274 the development of ASQ in various aspects to improve the robustness of evidence retrieval and 275 entity harmonization, as well as accessibility of evidence triangulation for researchers. 276

Whilst the ASQ platform offers a novel and accessible approach to querying a knowledge 277 graph, there are some important limitations. The extraction of claims from a piece of text is 278 rarely perfect, and genuine claims may be missed and others misinterpreted. The literature 279 knowledge based represented by SemMedDB is also subject to the same limitations (using the 280 same tool: SemRep), the triples extracted by SemRep are not context-specific (i.e. there is 281 no information about which section of an abstract these come from, so may reflect hypothesis 282 rather than conclusions) and in addition, literature evidence is subject to publication bias. The 283 association evidence in EpiGraphDB is constrained to a subset of published GWAS datasets 284 in OpenGWAS, and may omit important entities relating to claims in a query text. The ASQ 285 approach should therefore be considered as a support tool that aids evidence identification to 286 assess a claim, but not a comprehensive "fact-checker". 287

288 4 Methods

289 4.1 Entity harmonization

Here we denote a **taxonomy** as a catalogue of terms in a specific domain, and an **ontology** 290 as a tree representing the taxonomy terms in a hierarchical order (e.g. parent terms that are 291 more generic versus descendant terms with more specific meanings; Figure 3B). In that sense, 292 EFO is the ontology which ASQ uses to infer relationships between biomedical terms from the 293 taxonomies of UMLS and GWAS traits. This is because EpiGraphDB incorporates semantic 294 terms/triples in UMLS, but not its ontological hierarchies (since SemMedDB primarily curates 295 derived triples with mechanistic predicates such as "CAUSES" but not comprehensive ontolo-296 gies), and the GWAS traits are phenotypic trait names from genetic studies collated in the 297 OpenGWAS platform. An **entity** is then defined as a member of a taxonomy, i.e. a biomedical 298 concept can be represented in a taxonomy as one of its predefined members with an identifier 299 and a label (e.g. UMLS term C1305855 "Body mass index") to various degrees of semantic 300 affinity. Conceptually we refer to the process of resolving the mapping of terms from the claim 301 triple with those from EpiGraphDB evidence as entity harmonization, as it harmonizes entities 302 from different taxonomies into a unifying structure in the ontology (i.e. Figure 2). Our objective 303 is to retrieve entities from EpiGraphDB that are semantically similar and ontologically meaning-304 ful with respect to the query terms, while ensuring broader relevant terms are retrieved by not 305 restricting to identical token-level resemblance (which can also be achieved in ASQ by setting 306 very high semantic similarity thresholds). To this end ASQ retrieves EFO entities that would 307 sufficiently represent the query terms in the ontology hierarchy, then retrieve evidence entities 308 that are semantically similar to the selected EFO entities. 309

In ASQ we measure the proximity between two entities in the semantic space by the se-310 **mantic similarity** of their labels, which is calculated as the cosine similarity ([0,1]) between 311 the text embedding vectors of the labels. Specifically, ontology terms from the (Efo) nodes, 312 UMLS terms from the (LiteratureTerm) nodes, and GWAS traits from the (Gwas) nodes 313 are pre-encoded by ScispaCy²⁰ (en_core_sci_lg-0.4.0) into high-dimensional embed-314 ding vectors in an Elasticsearch vector store (Figure 1 left), which allows for fast retrieval of 315 candidate entities via a k-nearest neighbour (kNN) search of the pre-computed vectors against 316 the on-the-fly encoded vector of the query terms. On the one hand, entity representation via 317 fast text embeddings is a naive approach on its own and candidate retrieval based on cosine 318 similarity search can be highly sensitive to minor changes of the threshold, and on the other 319 hand, sophisticated classification of entity relationships requires real-time inferencing between 320 a large volume of candidate pairs using a dedicated classification model which is computa-321 tionally resource-heavy. Thus for entity harmonization we implemented a two-stage approach 322 that in the first stage the query terms are mapped to a handful of their close ontological repre-323 sentations in EFO, where simple semantic similarity measures are augmented by a dedicated 324 ontology classification process (discussed below), and in the second stage greater number of 325 evidence entities are retrieved for the corresponding EFO entities with kNN from the vector 326 store. This enables robust and efficient retrieval of entities and evidence by ASQ. 327

The entity harmonization process starts with the retrieval of candidate EFO entities that semantically resemble the query terms, where ASQ attempts to select EFO entities that would qualify as either identical ontological representations of the query terms or as closely associated members in the hierarchy based on their **identity score** ($[0, +\infty)$) with the query terms. The identity score is produced by BLUEBERT-EFO¹⁹ which we trained on the term mappings of EFO-

EFO terms and GWAS-EFO terms to infer the distance (number of steps/nodes) between a 333 query term and an EFO term in the ontology tree. An identity score of 0 suggests the two terms 334 are equivalent in the ontology, whereas a score of 1 suggests that the term of interest can be 335 considered as either a direct parent term or a direct descendant term of the reference ontology 336 term (in practice this can be relaxed to 1.5 as the inference model produces a *regression* score 337 rather than a *classification* score) and scores above 2 suggest greater distance between the 338 two terms. In previous research on the performance of entity retrieval by various methods¹⁹ 339 we showed that BLUEBERT-EFO as a task-specific bespoke model is able to retrieve candidate 340 terms that are closer to a term of interest in the semantic rankings, than naive embeddings from 341 general purpose models (e.g. ScispaCy, BioSentVec²¹, etc.). The retrieval of EFO candidates 342 is also augmented with a pre-filtering step to remove ontology candidate terms that are overly 343 generic to mitigate scenarios where retrieved evidence entities in subsequent steps are less 344 relevant to query terms due to these evidence entities being mapped to generic ontology terms 345 (such as an ontology term "disease"). This is done via the pre-computed information content 346 (IC) score of EFO terms using a scaled Sanchez Information Content²² ([0,1]) score where 347 terms closer to an end node of the EFO tree have scores closer to 1 and terms closer to the 348 origin have scores closer to 0. In both the interactive session and batch analysis mode, ASQ 349 by default (identity score < 1.5) seeks to select EFO candidates that would be either equivalent 350 in the ontology to the query term, or a first-degree neighbour of it, as the basis for evidence 351 identification, and in the interactive session users are able to further finetune the selection with 352 the rest of the retrieved EFO candidates. 353

354 4.2 Evidence retrieval

As discussed in Section 2.1, epidemiological knowledge in EpiGraphDB is represented as two 355 evidence groups in ASQ, i.e. the *triple and literature* group and the *association* group. From 356 another perspective, the claim triple as well as evidence items in the two evidence groups are 357 categorised by the **predicate group** according to whether for the claim or the evidence there is 358 an indication of direction or not. Claims with predicates in the set "AFFECTS", "CAUSES", "PRO-359 DUCES" and "TREATS" parsed from SemRep are *directional* claims whereas predicates in the 360 set "ASSOCIATED_WITH", "COEXISTS_WITH", and "INTERACTS_WITH" are non-directional 361 claims. The set of included predicates are determined by the availability of corresponding pred-362 icates in the (LiteratureTriple) component of EpiGraphDB (Table 1). Similarly statistical 363 results of association evidence are retrieved with predefined rules of predicate directions as 364 well (Table 3). When the query claim is directional, directional results from [MR_EVE_MR] are 365 retrieved as the basis of supporting/reversal/insufficient evidence types, and non-directional 366 results from [PRS] and [GEN_COR] are retrieved as the additional evidence type. When 367 the query claim is non-directional, results from all three sources are retrieved for the support-368 *ing/insufficient* evidence types. 369

The evidence types for each of the evidence groups and predicate groups are defined as below and summarised in Table 1:

• **Supporting** evidence items are those that provide sufficient evidence in support of the query claim. For *triple and literature* evidence, evidence from mapped literature terms which share the same predicate with the claim triple are *supporting* evidence. For *association* evidence, for *directional* claims, evidence from MR-EvE with strong statistical evidence (using P-Value as the parameter and default to P-Value $\leq 1e - 2$) are identified as the *supporting* evidence, whereas for *non-directional* claims, evidence is identified from MR-EvE, PRS, and GEN_COR with strong statistical evidence.

 Reversal evidence items are those that could sufficiently contradict the claim with iden-379 tified evidence from the reverse direction, and therefore is only applicable to *directional* 380 predicates. In other words, for a claim "Obesity CAUSES Asthma" evidence that would 381 support a claim "Asthma CAUSES Obesity" would be considered as a reversal evidence 382 item, because it reverses the direction. For both triple and literature evidence group and 383 association group, evidence item where its source node is a mapped evidence object 384 entity and its *target node* is a mapped *evidence subject* entity is identified as a reversal 385 evidence item. For association evidence the statistical threshold for supporting evidence 386 also applies. 387

Insufficient evidence items are identified as candidates for supporting evidence and reversal evidence (when applicable) which fail to meet the desired strength of evidence. This only applies to association evidence, for which P-Value is a quantitative measure. The aim of identifying insufficient evidence is to provide findings on the existence of systematic results, i.e. to determine whether the lack of evidence for a claim of interest is due to the absence of evidence (e.g. not curated by EpiGraphDB), or due to existing results failing to support/contradict a claim with sufficient strength.

Additional evidence items are identified as evidence that could be of potential interest to users for further investigation, but which may not be sufficiently specific to inform the acceptance or rejection of a claim. For association evidence, when the claim is directional, non-directional evidence from PRS and GEN_COR are candidates for additional evidence.

400

[Table 3 here]

401 4.3 Score metrics to measure retrieved evidence

We introduce scores for the retrieved evidence in order to facilitate the assessment of individual evidence items and provide a simple way to compare between evidence items and groups. However as naive assessment metrics they should be used for simple comparisons and should not replace the actual investigation into specific evidence details.

The mapping score P_{mapping} ([0,1]; Equation 1) of retrieved evidence measures the overall 406 deviation in terms of semantic similarity (S) between the retrieved evidence entities and the orig-407 inal query claim terms, which is a product of semantic similarity scores of associated entities in 408 the entity harmonization stage. A high score indicates that the retrieved evidence is of high se-409 mantic proximity to the query claim of interest, whereas a low score suggests that the semantic 410 relevance of the retrieved entity to the claim is low and therefore the relevance of the evidence 411 to the query should be discounted by the low semantic relevance. If multiple *i* EFO entities 412 are identified for a query term, but these map to the same evidence entity, the route with the 413 highest score value is chosen as the basis for mapping score calculation. In addition, for triple 414 entities the query terms are added as *pseudo*-ontology entities as they share the same UMLS 415 taxonomy. 416

$$P_{\text{mapping}} = \prod_{i} \max_{j} \left(S_{\text{query} \to \text{EFO}_{j}} \times S_{\text{EFO}_{j} \to \text{evidence}} \right), i \in [\text{subject}, \text{object}]$$
(1)

For *triple and literature* evidence, the strength of the evidence $P_{T\&L.}$ ([1, + ∞); Equation 2a) is measured by the number of source literature items containing the semantic triple evidence. The baseline for the evidence score is 1 where the semantic triple is associated with 1 source literature article. Therefore the *evidence score* for *triple and literature* evidence $E_{T\&L.}$ ([0, + ∞); Equation 2b) is a product of the evidence strength and mapping score, where in a typical scenario when there is an exact mapping (mapping score 1) of the involved entities and there is 1 source literature article the individual evidence item will have a baseline score of 1.

$$P_{\mathsf{T\&L.}} = 1 + log_{10}N_{\mathsf{literature}}$$
(2a)

$$E_{\mathsf{T\&L.}} = P_{\mathsf{mapping}} \times P_{\mathsf{T\&L.}} \tag{2b}$$

For association evidence, the strength of the evidence $P_{\text{Assoc.}}$ ([0, + ∞); Equation 3a) is measured with the standardized effect size of the statistical results where a unit absolute standardized effect size produces a score of 1 as the baseline. Similarly the evidence score for *association* evidence $E_{\text{Assoc.}}$ ([0, + ∞); Equation 3b) is the product of the mapping status and the association evidence strength.

$$P_{\text{Assoc.}} = \max\left(0, 1 + \log_{10}\left|\frac{\beta}{\sigma}\right|\right)$$
(3a)

$$E_{\mathsf{Assoc.}} = P_{\mathsf{mapping}} imes P_{\mathsf{Assoc.}}$$

ASQ calculates the aggregate score and average score for each of the evidence groups 429 and evidence types. Simple comparisons could be made (but should not be the substitute 430 for further investigations) in cases such as between the supporting evidence group and rever-431 sal evidence group of a claim, as well as between two supporting evidence items. However 432 comparisons between the supporting evidence group and the insufficient/additional evidence 433 groups via quantitative measures are not appropriate as insufficient/additional evidence types 434 by definition do not assess the query claim by metrics, and should instead be interpreted by 435 the user based on their own knowledge. Similarly comparisons between the triple and literature 436 group and the *association* group by metrics is not appropriate as they do not share a common 437 measurement unit for their scores. 438

Code availability

Source code for the ASQ platform and relevant analysis scripts can be found via https://

441 github.com/mrcieu/epigraphdb-asq. Tutorial on programmatically accessing the ASQ

442 platform can be found via this Jupyter notebook https://github.com/MRCIEU/epigraphdb-asq/

443 blob/master/analysis/notebooks/programmatic-access.ipynb.

444 Funding

⁴⁴⁵ This work was supported by the UK Medical Research Council Integrative Epidemiology Unit ⁴⁴⁶ [MC UU_00011/4] and the University of Bristol.

447 **Conflicts of interest**

⁴⁴⁸ T.R.G. receives funding from Biogen for unrelated research.

(3b)

449 **References**

- Lawlor, D. A., Tilling, K. & Davey Smith, G. Triangulation in aetiological epidemiology.
 Int. J. Epidemiol. 45, 1866–1886, 10.1093/ije/dyw314 (2017). https://academic.oup.com/ije/
 article-pdf/45/6/1866/32531204/dyw314.pdf.
- **2.** Ochoa, D. *et al.* Open targets platform: supporting systematic drug–target identification and prioritisation. *Nucleic Acids Res.* **49**, D1302–D1310 (2021).
- **3.** Liu, Y. *et al.* EpiGraphDB: a database and data mining platform for health data science. *Bioinformatics* **37**, 1304–1311, 10.1093/bioinformatics/btaa961 (2020). https://academic.oup. com/bioinformatics/article-pdf/37/9/1304/38575106/btaa961.pdf.
- **4.** Shefchek, K. A. *et al.* The monarch initiative in 2019: an integrative data and analytic platform connecting phenotypes to genotypes across species. *Nucleic acids research* **48**, D704–D715 (2020).
- **5.** Malone, J. *et al.* Modeling sample variables with an experimental factor ontology. *Bioinformatics* **26**, 1112–1118 (2010).
- 6. Elsworth, B. *et al.* The MRC IEU OpenGWAS data infrastructure. *bioRxiv* 10.1101/2020.08.
 10.244293 (2020). https://www.biorxiv.org/content/early/2020/08/10/2020.08.10.244293.full.pdf.
- **7.** Kilicoglu, H., Shin, D., Fiszman, M., Rosemblat, G. & Rindflesch, T. C. Semmeddb: a
 pubmed-scale repository of biomedical semantic predications. *Bioinformatics* 28, 3158–3160 (2012).
- **8.** Medrxiv.org the preprint server for health sciences.
- **9.** Kilicoglu, H., Rosemblat, G., Fiszman, M. & Shin, D. Broad-coverage biomedical relation extraction with semrep. *BMC bioinformatics* **21**, 1–28 (2020).
- **10.** Schuyler, P. L., Hole, W. T., Tuttle, M. S. & Sherertz, D. D. The umls metathesaurus: representing different views of biomedical concepts. *Bull. Med. Libr. Assoc.* **81**, 217 (1993).
- 11. UMLS Reference Manual, chap. Semantic Network (National Library of Medicine, 2009).
- Hemani, G. *et al.* Automating mendelian randomization through machine learning to construct a putative causal map of the human phenome. *bioRxiv* 10.1101/173682 (2017).
 https://www.biorxiv.org/content/early/2017/08/23/173682.full.pdf.
- **13.** Abbot, L., Neale, B. & Palmer, D. Genetic correlation between traits and disorders in the UK biobank. Tech. Rep., Neale Lab, Analytical and Translation Genetics Unit (2020).
- **14.** Richardson, T. G., Harrison, S., Hemani, G. & Smith, G. D. An atlas of polygenic risk score associations to highlight putative causal relationships across the human phenome. *Elife* 8, e43657 (2019).
- Lumbers, R. T. *et al.* Body mass index and heart failure risk: a cohort study in 1.5 million individuals and mendelian randomisation analysis. *medRxiv* 10.1101/2020.09.23.20200360 (2020). https://www.medrxiv.org/content/early/2020/09/25/2020.09.23.20200360.1.full.pdf.
- **16.** Sardu, C., De Lucia, C., Wallner, M. & Santulli, G. Diabetes mellitus and its cardiovascular complications: new insights into an old disease (2019).
- **17.** Baena-Díez, J. M. *et al.* Obesity is an independent risk factor for heart failure: Zona franca cohort study. *Clin. cardiology* **33**, 760–764 (2010).

- **18.** Goncalves, G. K., de Oliveira, T. H. C. & de Oliveira Belo, N. Cardiac hypertrophy and brain
 natriuretic peptide levels in an ovariectomized rat model fed a high-fat diet. *Med. Sci. Monit. Basic Res.* 23, 380 (2017).
- **19.** Elsworth, B., Liu, Y. & Gaunt, T. R. Using language models and ontology topology to perform semantic mapping of traits between biomedical datasets. *medRxiv* (Forthcoming).
- Neumann, M., King, D., Beltagy, I. & Ammar, W. ScispaCy: Fast and Robust Models for
 Biomedical Natural Language Processing. In *Proceedings of the 18th BioNLP Workshop and Shared Task*, 319–327, 10.18653/v1/W19-5034 (Association for Computational Linguis tics, Florence, Italy, 2019). arXiv:1902.07669.
- 21. Chen, Q., Peng, Y. & Lu, Z. Biosentvec: creating sentence embeddings for biomedical texts. In *2019 IEEE International Conference on Healthcare Informatics (ICHI)*, 1–5 (IEEE, 2019).
- 22. Sánchez, D. & Batet, M. A new model to compute the information content of concepts from taxonomic knowledge. *Int. J. Semantic Web Inf. Syst.* 8, 34–50 (2012).

Figures & Tables

504 **Tables**

Table 1. Integration of epidemiological evidence in EpiGraphDB

Distribution of the EpiGraphDB *knowledge* triples which are the *source* evidence in this study, harmonized into the two evidence categories. Column "Triples" and column "Literature" report respectively the number of literature triples and number of associated source literature articles in a triple and literature evidence group, and column "Associations" report the number of statistical associations in an association evidence group. For example, there are 37,423 literature triples in the form of Term 1 AFFECTS Term 2 where Term 1 and Term 2 are from the term types of aapp ("Amino Acid, Peptide, or Protein"), dsyn ("Disease or Syndrome"), gngm ("Gene or Genome") (a UMLS term can have multiple associated types), and there are 57,928 source literature articles from which the 37,423 literature triples are derived. Similarly, there are 8,966,440 statistical associations from the MR-EvE study¹² between GWAS-es in the UKBiobank categories (ukb-a, ukb-b, etc.) of OpenGWAS⁶. A UMLS term can have multiple associated semantic types and the label descriptions on UMLS semantic types are available in Supplementary Table 1.

| Triple and literature evidence | | | | | | | | |
|--------------------------------|------------------|------------------------|--------------|------------|--|--|--|--|
| Direction | UMLS Predicate | UMLS term type | Triples | Literature | | | | |
| Directional | AFFECTS | aapp, dsyn, gngm | 37,243 | 57,928 | | | | |
| | AFFECTS | dsyn | 29,167 | 58,753 | | | | |
| | CAUSES | dsyn | 85,231 | 222,462 | | | | |
| | CAUSES | aapp, dsyn, gngm | 49,178 | 100,681 | | | | |
| | TREATS | phsu, dsyn, orch | 82,263 | 274,589 | | | | |
| | TREATS | phsu, dsyn | 47,416 | 238,636 | | | | |
| | PRODUCES | aapp, gngm | 69,691 | 106,862 | | | | |
| | PRODUCES | phsu, aapp, gngm | 12,706 | 26,122 | | | | |
| Non-directional | ASSOCIATED_WITH | aapp, dsyn, gngm | 188,961 | 423,727 | | | | |
| | ASSOCIATED_WITH | phsu, aapp, dsyn, gngm | 29,425 | 86,176 | | | | |
| | INTERACTS_WITH | aapp, gngm | 393,759 | 673,470 | | | | |
| | COEXISTS_WITH | aapp, gngm | 224,098 | 332,834 | | | | |
| | COEXISTS_WITH | dsyn | 150,166 | 385,349 | | | | |
| | INTERACTS_WITH | aapp, enzy, gngm | 72,194 | 140,836 | | | | |
| | As | ssociation evidence | | | | | | |
| Direction | Association type | GWAS categories | Associations | | | | | |
| Directional | MR_EVE_MR | ukb, ukb | 8,966,440 | | | | | |
| | MR_EVE_MR | prot, ukb | 5,028,904 | | | | | |
| | MR_EVE_MR | ubm, ukb | 3,833,948 | | | | | |
| | MR_EVE_MR | prot, prot | 3,109,406 | | | | | |
| | MR_EVE_MR | prot, ubm | 1,974,611 | | | | | |
| Non-directional | GEN_COR | ukb-b, ukb-b | 453,752 | | | | | |
| | GEN_COR | ukb-a, ukb-b | 286,536 | | | | | |
| | GEN_COR | ukb-a, ukb-a | 180,536 | | | | | |
| | GEN_COR | ukb-b, ukb-d | 133,554 | | | | | |
| | GEN_COR | ukb-a, ukb-d | 84,266 | | | | | |
| | GEN_COR | ukb-d, ukb-d | 38,908 | | | | | |
| | PRS | ieu-a, ukb-a | 70,926 | | | | | |
| | PRS | ukb-b, ieu-a | 45,394 | | | | | |
| | PRS | ukb-a, ukb-a | 2,198 | | | | | |
| | PRS | ukb-b, ukb-a | 704 | | | | | |

Table 2. Systematic analysis results: top claim terms by retrieved evidence

Top claim terms sorted by the number of cases where the query claim triple is associated with both triple and literature evidence as well as association evidence ("T&L. + Assoc."). For example, there are 41 claim triples involving the term "Disease" as either a subject term or an object term where these claim triples are identified with *both* supporting evidence in triple and literature evidence ("T&L.") and association evidence ("Assoc.") groups, 74 cases identified with supporting triple evidence, 44 cases identified with supporting association evidence, 77 cases identified with any evidence types ("Any"; See Section 4.2 and Table 3 for all evidence types), and 715 cases from the triples in the initial claim parsing stage dataset ("Init."; Figure 4) after parsing from source abstracts regardless of results in the downstream stages.

| Claim term | Supporting | | | Any | Init. |
|---------------------------------|---------------|------|--------|-----|-------|
| | T&L. + Assoc. | T&L. | Assoc. | | |
| Disease | 41 | 74 | 44 | 77 | 715 |
| Obesity | 20 | 25 | 25 | 30 | 125 |
| Diabetes | 17 | 19 | 18 | 20 | 87 |
| Depressive disorder | 14 | 20 | 16 | 26 | 100 |
| Parkinson Disease | 13 | 13 | 13 | 13 | 111 |
| Diabetes Mellitus, Non-Insulin- | 10 | 12 | 12 | 15 | 84 |
| Dependent | | | | | |
| Alzheimer's Disease | 8 | 10 | 8 | 10 | 111 |
| Schizophrenia | 8 | 11 | 8 | 11 | 32 |
| C-reactive protein | 7 | 7 | 9 | 10 | 24 |
| Malignant Neoplasms | 7 | 8 | 15 | 19 | 100 |
| Chronic Kidney Diseases | 6 | 9 | 6 | 9 | 35 |
| Chronic disease | 5 | 6 | 5 | 6 | 44 |
| Fatigue | 5 | 5 | 6 | 6 | 25 |
| Sleep | 5 | 5 | 6 | 6 | 21 |
| Atrial Fibrillation | 5 | 6 | 6 | 9 | 57 |
| Pain | 4 | 4 | 6 | 6 | 30 |
| Glucose | 4 | 5 | 4 | 6 | 20 |
| Blood Glucose | 4 | 5 | 4 | 5 | 15 |
| Hypertensive disease | 4 | 12 | 4 | 13 | 90 |
| Mental disorders | 4 | 8 | 4 | 10 | 42 |
| Cardioembolic stroke | 3 | 3 | 3 | 3 | 14 |
| Testosterone | 3 | 5 | 3 | 6 | 21 |
| Diabetes Mellitus | 3 | 4 | 5 | 6 | 25 |
| Triglycerides | 3 | 4 | 4 | 5 | 16 |
| Heart Diseases | 3 | 3 | 3 | 3 | 10 |
| Unipolar Depression | 3 | 4 | 3 | 4 | 32 |
| Myocardial Infarction | 3 | 4 | 5 | 6 | 15 |
| Malignant neoplasm of prostate | 3 | 4 | 3 | 4 | 18 |
| Enthesitis-Related Arthritis | 3 | 4 | 3 | 4 | 25 |
| Behavior | 3 | 3 | 3 | 4 | 13 |

Table 3. Classification of retrieved evidence

Summary of how retrieved evidence items are classified based on the **predicate direction group**, **evidence group**, and **evidence type**. The notation $S - P \rightarrow O$ means a Subject PREDICATE Object triple where the predicate is directional (e.g. a "CAUSES" predicate versus a non-directional predicate "ASSOCIATED_WITH") and the notation $S - P \rightarrow O$ means a triple with non-directional predicate.

| | Supporting | Reversal | Insufficient | Additional | | | |
|--|--------------------------------------|--------------------------------------|---|-----------------------------|--|--|--|
| Directional predicates | | | | | | | |
| | CAUS | SES, TREATS, PRODUCES, | AFFECTS | | | | |
| Triple and literature | $S - P \rightarrow O$ | $O - P \rightarrow S$ | N/A | N/A | | | |
| Association | $S-P \rightarrow O, P_P-Value < \pi$ | $O-P \rightarrow S, P_P-Value < \pi$ | $S-P \rightarrow O, P_P-Value \geq \pi$ | non-directional $S - P - O$ | | | |
| Non-directional predicates | | | | | | | |
| INTERACTS_WITH, COEXISTS_WITH, ASSOCIATED_WITH | | | | | | | |
| Triple and literature | S-P-O | N/A | N/A | N/A | | | |
| Association | $S-P-O, P_P-Value < \pi$ | N/A | $S-P-O, P_P-Value \geq \pi$ | N/A | | | |

505 Figures



Figure 1. Architecture of the EpiGraphDB-ASQ platform

Overall architecture design of the EpiGraphDB-ASQ platform and its associated components in the EpiGraphDB ecosystem. Left: EpiGraphDB's biomedical entities (in the form of graph nodes) from different taxonomies are encoded into vector representations which allows for fast information retrieval against the query of interest. Epidemiological evidence (in the form of graph edges) are incorporated into ASQ as harmonized evidence groups. **Right**: Internal processing workflow of the EpiGraphDB-ASQ platform by the three stages: the claim parsing stage, the entity harmonization stage, and the evidence retrieval stage.



Figure 2. Evidence triangulation regarding scientific claims

A summary network diagram on the retrieved entities and evidence from the ASQ platform regarding a claim "Glucose TREATS Diabetes". The subject and object terms of the query claim are represented as nodes in red, and the predicate as a directed edge. The ontology term (green nodes) "glucose" is identified as the mapped term for the claim subject, and ontology terms "diabetes mellitus", "monogenic diabetes", "Maternal diabetes" are identified as the mapped terms for the claim object in the default setting (which can be adjusted at an interactive session or updated after initial results). Triple and literature evidence are represented as semantic triples (deep blue nodes) formed by UMLS Metathesaurus terms (light blue nodes), which are linked to source literature findings (pink nodes). For association evidence, statistical association results on GWAS traits (blue nodes) are represented as edges between them. Edges in dashed lines represent mappings between taxonomies, and edges in solid lines represent evidence items.



Figure 3. Overview of web interface

Overview of the web interface functionalities of EpiGraphDB-ASQ. **A**: Summary of harmonized entities and retrieved evidence regarding the query claim. **B**: Sub-graph representation of a retrieved ontology entity in the EFO graph. **C**: Summarised literature information and context details for a retrieved semantic triple "Obesity CAUSES Asthma". **D**: Forest plot on the statistical association evidence regarding the query claim.



Figure 4. Study design of the systematic analysis and result metrics

Overview diagram on the systematic analysis results and the primary metrics in the various stages discussed in Section 2.2. This figure complements Figure 1 regarding an individual case with the aspect of systematic scale. Further discussions on the parameter configuration as shown in each of the stages are available in Supplementary Table 5.



Figure 5. Entity harmonization stage: distribution of score metrics of retrieved EFO entities

Distribution of semantic similarity scores, information content scores, and identity scores for retrieved EFO entities in the process of mapping with query UMLS terms, categorised by the semantic type of the UMLS term ("term_type") and score metrics ("score_type") in the retrieval process.

Category type: "candidate" for entities retrieved as a candidate, "select" for candidates that are selected in the automated process (Section 4.1), and "not_select" for candidates that are not selected.

Left ("all"): Distribution across all semantic types. Middle 1 ("dsyn"): In the "Disease or Syndrome" group. Middle 2 ("mobd"): In the "Mental or Behavioral Dysfunction" group. Right ("neop"): In the "Neoplastic Process" group. This figure reports distributions in the top 3 semantic type groups by entity count (Supplementary Table 7 reports entity counts of all semantic types).

Top ("similarity"): By semantic similarity score to measure similarity of term embedding vectors. **Center** ("ic"): By information content score to measure the concreteness of the term in EFO. **Bottom** ("identity"): By identity score to measure the inferred relative distance of the UMLS term. The roles of the score metrics take in the harmonization retrieval process are discussed in detail in Section 4.1. Supplementary figure 1 reports the distribution of score metrics for retrieved UMLS and trait entities.



Figure 6. Evidence retrieval stage: distribution of evidence scores and constituent scores

Distribution of evidence scores and its constituent scores (entity mapping scores and evidence strength scores), for the "supporting", "reversal", and "insufficient" evidence types (by rows) in the triple and literature evidence group and the association evidence group (by columns). This figure reports aggregated distributions across directional and non-directional predicate groups, and Supplementary Tables 4 and 5 report detailed distributions by evidence groups, evidence types, and predicate groups. Note an "insufficient" evidence type is only applicable to the association ("assoc") evidence group and not the triple and literature ("triple") evidence group.



Figure 7. Systematic analysis results: evidence clusters of topic terms

Clusters representing research interests as parsed from the MedRxiv abstract sample from 2020-01-01 to 2021-12-31 as well as their corresponding evidence retrieved from EpiGraphDB-ASQ as network diagrams. Nodes coloured in red correspond to the primary claim terms (Table 2) and edges coloured in red correspond to relationships involving a primary claim term. **A**: Obesity cluster with primary terms "Obesity", "Diabetes", "Diabetes", "Diabetes", "Diabetes", "Chronic Kidney Diseases"; **B**: Mental illness cluster with primary terms "Depressive disorder", "Alzheimer's Disease", "Schizophrenia", "Parkinson Disease"; **C**: COVID-19 cluster with primary terms "Coronavirus infections"; The diagrams are generated by retrieving first-degree neighbour nodes for each of the top term nodes, where node size corresponds to term count, and edge width correspond to aggregated supporting evidence scores between nodes. Interactive diagram is available on https://asq.epigraphdb.org/medrxiv-analysis.